You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClenbuterol
Accession NumberDB01407
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. [PubChem]
Structure
Thumb
Synonyms
(+-)-Clenbuterol
(±)-clenbuterol
1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol
4-amino-3,5-Dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol
4-amino-alpha-((Tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol
4-amino-α-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol
CLENBUTEROL
Clenbuterolum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MonoresValeas
SpiropentBoehringer Ingelheim
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Clenbuterol hydrochloride
ThumbNot applicableDBSALT001621
Categories
UNIIXTZ6AXU7KN
CAS number37148-27-9
WeightAverage: 277.19
Monoisotopic: 276.079618622
Chemical FormulaC12H18Cl2N2O
InChI KeySTJMRWALKKWQGH-UHFFFAOYSA-N
InChI
InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3
IUPAC Name
1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethan-1-ol
SMILES
CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1
Pharmacology
IndicationUsed as a bronchodilator in the treatment of asthma patients.
Structured Indications Not Available
PharmacodynamicsClenbuterol is a substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. Although approved for use in some countries, as of fall, 2006, clenbuterol is not an ingredient of any therapeutic drug approved by the U.S. Food and Drug Administration.
Mechanism of actionClenbuterol is a Beta(2) agonist similar in some structural respects to salbutamol. Agonism of the beta(2) receptor stimulates adenylyl cyclase activity which ultimately leads to downstream effects of smooth muscle relaxation in the bronchioles.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-2 adrenergic receptorProteinyes
agonist
HumanP07550 details
Beta-1 adrenergic receptorProteinunknown
agonist
HumanP08588 details
Beta-3 adrenergic receptorProteinunknown
agonist
HumanP13945 details
Beta-nerve growth factorProteinunknown
stimulator
HumanP01138 details
Tumor necrosis factorProteinunknown
other/unknown
HumanP01375 details
Related Articles
Absorption89-98% orally
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life36-39 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Clenbuterol.Experimental
AbirateroneThe serum concentration of Clenbuterol can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may decrease the bronchodilatory activities of Clenbuterol.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Clenbuterol.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clenbuterol.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Clenbuterol.Approved, Illicit
AtenololAtenolol may decrease the bronchodilatory activities of Clenbuterol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Clenbuterol.Approved
AtosibanThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Atosiban.Approved
AzithromycinThe metabolism of Clenbuterol can be decreased when combined with Azithromycin.Approved
BendroflumethiazideClenbuterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Clenbuterol.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Clenbuterol.Approved, Illicit
Benzylpenicilloyl PolylysineClenbuterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Clenbuterol can be decreased when used in combination with Betahistine.Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Clenbuterol.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Clenbuterol.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Clenbuterol.Approved
BortezomibThe metabolism of Clenbuterol can be decreased when combined with Bortezomib.Approved, Investigational
BromocriptineBromocriptine may increase the hypertensive activities of Clenbuterol.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Bucindolol.Investigational
BumetanideClenbuterol may increase the hypokalemic activities of Bumetanide.Approved
BupranololBupranolol may decrease the bronchodilatory activities of Clenbuterol.Approved
CabergolineCabergoline may increase the hypertensive activities of Clenbuterol.Approved
CaffeineThe metabolism of Clenbuterol can be decreased when combined with Caffeine.Approved
CarbamazepineThe metabolism of Clenbuterol can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Clenbuterol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Clenbuterol.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational
ChlorothiazideClenbuterol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Chlorphentermine.Illicit, Withdrawn
ChlorthalidoneClenbuterol may increase the hypokalemic activities of Chlorthalidone.Approved
CitalopramThe metabolism of Clenbuterol can be decreased when combined with Citalopram.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Clenbuterol.Approved, Vet Approved
ClotrimazoleThe metabolism of Clenbuterol can be decreased when combined with Clotrimazole.Approved, Vet Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clenbuterol.Approved
Cyproterone acetateThe serum concentration of Clenbuterol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DeferasiroxThe serum concentration of Clenbuterol can be increased when it is combined with Deferasirox.Approved, Investigational
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clenbuterol.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Clenbuterol.Approved
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Clenbuterol.Approved
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Clenbuterol.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Clenbuterol.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Clenbuterol.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Clenbuterol.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Clenbuterol.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Doxofylline.Approved
DronabinolDronabinol may increase the tachycardic activities of Clenbuterol.Approved, Illicit
DuloxetineDuloxetine may increase the tachycardic activities of Clenbuterol.Approved
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Clenbuterol.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Clenbuterol.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Clenbuterol.Approved
ErgonovineErgonovine may increase the hypertensive activities of Clenbuterol.Approved
ErgotamineErgotamine may increase the hypertensive activities of Clenbuterol.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Clenbuterol.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Clenbuterol.Approved
Etacrynic acidClenbuterol may increase the hypokalemic activities of Etacrynic acid.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Etilefrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Clenbuterol.Approved
FluvoxamineThe metabolism of Clenbuterol can be decreased when combined with Fluvoxamine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Clenbuterol.Approved, Vet Approved
FurosemideClenbuterol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Clenbuterol.Approved
HydrochlorothiazideClenbuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideClenbuterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Hydroxyamphetamine hydrobromide.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clenbuterol.Approved
IndapamideClenbuterol may increase the hypokalemic activities of Indapamide.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Clenbuterol.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Clenbuterol.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Clenbuterol.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Clenbuterol.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clenbuterol.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Clenbuterol.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Isoxsuprine.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Clenbuterol.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Clenbuterol.Approved
LidocaineThe metabolism of Clenbuterol can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidLinezolid may increase the hypertensive activities of Clenbuterol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Clenbuterol.Withdrawn
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Clenbuterol.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Clenbuterol.Approved, Investigational
MethamphetamineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Methamphetamine.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Clenbuterol.Approved
MethyclothiazideClenbuterol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Clenbuterol.Investigational
MetolazoneClenbuterol may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational
MexiletineThe metabolism of Clenbuterol can be decreased when combined with Mexiletine.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Clenbuterol.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Clenbuterol.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Clenbuterol.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clenbuterol.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clenbuterol.Approved
NabiloneNabilone may increase the tachycardic activities of Clenbuterol.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Clenbuterol.Approved
NebivololNebivolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational
NevirapineThe metabolism of Clenbuterol can be decreased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Clenbuterol.Withdrawn
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Clenbuterol.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clenbuterol.Approved
NylidrinThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Clenbuterol.Withdrawn
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Clenbuterol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Clenbuterol.Approved
OsimertinibThe serum concentration of Clenbuterol can be decreased when it is combined with Osimertinib.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Clenbuterol.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Clenbuterol.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Clenbuterol.Approved
Peginterferon alfa-2bThe serum concentration of Clenbuterol can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clenbuterol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Clenbuterol.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Clenbuterol.Approved, Illicit
PhenobarbitalThe metabolism of Clenbuterol can be increased when combined with Phenobarbital.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Clenbuterol.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Clenbuterol.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Clenbuterol.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Clenbuterol.Approved, Vet Approved, Withdrawn
PindololPindolol may decrease the bronchodilatory activities of Clenbuterol.Approved
PiretanideClenbuterol may increase the hypokalemic activities of Piretanide.Experimental
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Clenbuterol.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Clenbuterol.Withdrawn
PolythiazideClenbuterol may increase the hypokalemic activities of Polythiazide.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Clenbuterol.Approved
PrimidoneThe metabolism of Clenbuterol can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Clenbuterol.Approved
PropranololPropranolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clenbuterol.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Pseudoephedrine.Approved
QuinethazoneClenbuterol may increase the hypokalemic activities of Quinethazone.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Racepinephrine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clenbuterol.Approved
RifampicinThe metabolism of Clenbuterol can be increased when combined with Rifampicin.Approved
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Clenbuterol.Approved
RopiniroleThe metabolism of Clenbuterol can be decreased when combined with Ropinirole.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Clenbuterol.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Clenbuterol.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Clenbuterol.Approved
SimeprevirThe metabolism of Clenbuterol can be decreased when combined with Simeprevir.Approved
SotalolSotalol may decrease the bronchodilatory activities of Clenbuterol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Clenbuterol.Approved
SynephrineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Clenbuterol.Approved
TenofovirThe metabolism of Clenbuterol can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinTerazosin may decrease the vasoconstricting activities of Clenbuterol.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Clenbuterol.Approved
TeriflunomideThe serum concentration of Clenbuterol can be decreased when it is combined with Teriflunomide.Approved
TetryzolineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Tetryzoline.Approved
TheophyllineThe metabolism of Clenbuterol can be decreased when combined with Theophylline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Clenbuterol.Approved
TiclopidineThe metabolism of Clenbuterol can be decreased when combined with Ticlopidine.Approved
TimololTimolol may decrease the bronchodilatory activities of Clenbuterol.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Clenbuterol.Approved
TorasemideClenbuterol may increase the hypokalemic activities of Torasemide.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clenbuterol.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clenbuterol.Approved
TrichlormethiazideClenbuterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Clenbuterol.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clenbuterol.Approved
TyramineThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Tyramine.Investigational, Nutraceutical
VemurafenibThe serum concentration of Clenbuterol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Clenbuterol.Approved
Food InteractionsNot Available
References
Synthesis ReferenceKeck, J., Kruger, G., Machleidt, H., Noll, K., Engelhardt, G. and Eckenfels, A.; U S . Patent

3,536,712; October 27,1970: assigned to Boehringer lngelheim G.m.b.H. (Germany).

General ReferencesNot Available
External Links
ATC CodesR03CC13R03AC14
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9484
Blood Brain Barrier+0.8631
Caco-2 permeable+0.5375
P-glycoprotein substrateSubstrate0.5588
P-glycoprotein inhibitor INon-inhibitor0.8863
P-glycoprotein inhibitor IINon-inhibitor0.9627
Renal organic cation transporterNon-inhibitor0.9052
CYP450 2C9 substrateNon-substrate0.8142
CYP450 2D6 substrateNon-substrate0.683
CYP450 3A4 substrateNon-substrate0.5835
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5428
Ames testNon AMES toxic0.8858
CarcinogenicityNon-carcinogens0.5199
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6024 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9704
hERG inhibition (predictor II)Non-inhibitor0.8546
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point174-175.5Keck, J., Kruger, G., Machleidt, H., Noll, K., Engelhardt, G. and Eckenfels, A.; U S . Patent 3,536,712; October 27,1970: assigned to Boehringer lngelheim G.m.b.H. (Germany).
Predicted Properties
PropertyValueSource
Water Solubility0.112 mg/mLALOGPS
logP2.94ALOGPS
logP2.33ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)14.06ChemAxon
pKa (Strongest Basic)9.63ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area58.28 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity73.38 m3·mol-1ChemAxon
Polarizability28.81 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as substituted anilines. These are organic compound containing an aniline group substituted at one or more positions.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAnilines
Direct ParentSubstituted anilines
Alternative Parents
Substituents
  • Substituted aniline
  • 1,3-dichlorobenzene
  • Aralkylamine
  • Halobenzene
  • Chlorobenzene
  • Primary aromatic amine
  • Aryl halide
  • Aryl chloride
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Zhu Y, Culmsee C, Roth-Eichhorn S, Krieglstein J: Beta(2)-adrenoceptor stimulation enhances latent transforming growth factor-beta-binding protein-1 and transforming growth factor-beta1 expression in rat hippocampus after transient forebrain ischemia. Neuroscience. 2001;107(4):593-602. [PubMed:11720783 ]
  2. Ryall JG, Gregorevic P, Plant DR, Sillence MN, Lynch GS: Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Regul Integr Comp Physiol. 2002 Dec;283(6):R1386-94. Epub 2002 Sep 5. [PubMed:12388476 ]
  3. Choo JJ, Horan MA, Little RA, Rothwell NJ: Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. Am J Physiol. 1992 Jul;263(1 Pt 1):E50-6. [PubMed:1322047 ]
  4. Sillence MN, Matthews ML, Spiers WG, Pegg GG, Lindsay DB: Effects of clenbuterol, ICI118551 and sotalol on the growth of cardiac and skeletal muscle and on beta 2-adrenoceptor density in female rats. Naunyn Schmiedebergs Arch Pharmacol. 1991 Oct;344(4):449-53. [PubMed:1685013 ]
  5. Mazzanti G, Di Sotto A, Daniele C, Battinelli L, Brambilla G, Fiori M, Loizzo S, Loizzo A: A pharmacodynamic study on clenbuterol-induced toxicity: beta1- and beta2-adrenoceptors involvement in guinea-pig tachycardia in an in vitro model. Food Chem Toxicol. 2007 Sep;45(9):1694-9. Epub 2007 Mar 12. [PubMed:17449161 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Baker JG: The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010 Jul;160(5):1048-61. doi: 10.1111/j.1476-5381.2010.00754.x. [PubMed:20590599 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Baker JG: The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010 Jul;160(5):1048-61. doi: 10.1111/j.1476-5381.2010.00754.x. [PubMed:20590599 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
stimulator
General Function:
Receptor signaling protein activity
Specific Function:
Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades through those receptor tyrosine kinase to regulate neuronal proliferation, differentiation and survival. Inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI (PubM...
Gene Name:
NGF
Uniprot ID:
P01138
Molecular Weight:
26958.53 Da
References
  1. Culmsee C, Semkova I, Krieglstein J: NGF mediates the neuroprotective effect of the beta2-adrenoceptor agonist clenbuterol in vitro and in vivo: evidence from an NGF-antisense study. Neurochem Int. 1999 Jul;35(1):47-57. [PubMed:10403429 ]
  2. Semkova I, Krieglstein J: Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain Res Brain Res Rev. 1999 Aug;30(2):176-88. [PubMed:10525174 ]
  3. Puls I, Beck M, Giess R, Magnus T, Ochs G, Toyka KV: [Clenbuterol in amyotrophic lateral sclerosis. No indication for a positive effect]. Nervenarzt. 1999 Dec;70(12):1112-5. [PubMed:10637819 ]
  4. Samina Riaz S, Tomlinson DR: Pharmacological modulation of nerve growth factor synthesis: a mechanistic comparison of vitamin D receptor and beta(2)-adrenoceptor agonists. Brain Res Mol Brain Res. 2000 Dec 28;85(1-2):179-88. [PubMed:11146120 ]
  5. Riaz SS, Tomlinson DR: Clenbuterol stimulates neurotrophic support in streptozotocin-diabetic rats. Diabetes Obes Metab. 1999 Jan;1(1):43-51. [PubMed:11221812 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Izeboud CA, Mocking JA, Monshouwer M, van Miert AS, Witkamp RF: Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):191-202. [PubMed:10071758 ]
  2. Yoshimura T: [Modulation of cytokine production from human mononuclear cells by several agents]. Yakugaku Zasshi. 2000 Dec;120(12):1277-90. [PubMed:11193379 ]
  3. Izeboud CA, Hoebe KH, Grootendorst AF, Nijmeijer SM, van Miert AS, Witkamp RR, Rodenburg RJ: Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. Inflamm Res. 2004 Mar;53(3):93-9. Epub 2004 Feb 16. [PubMed:15021963 ]
  4. Laan TT, Bull S, Pirie RS, Fink-Gremmels J: Evaluation of cytokine production by equine alveolar macrophages exposed to lipopolysaccharide, Aspergillus fumigatus, and a suspension of hay dust. Am J Vet Res. 2005 Sep;66(9):1584-9. [PubMed:16261833 ]
  5. van den Hoven R, Duvigneau JC, Hartl RT, Gemeiner M: Clenbuterol affects the expression of messenger RNA for interleukin 10 in peripheral leukocytes from horses challenged intrabronchially with lipopolysaccharides. Vet Res Commun. 2006 Nov;30(8):921-8. [PubMed:17139543 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 17, 2007 06:33 / Updated on August 17, 2016 12:23